Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics (RNTX)
NASDAQ:RNTX
Total Valuation
Rein Therapeutics has a market cap or net worth of $25.58M. The enterprise value is $25.80M.
Market Cap$25.58M
Enterprise Value$25.80M
Share Statistics
Rein Therapeutics has 23,046,122 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,046,122
Owned by Insiders2.08%
Owned by Institutions0.61%
Financial Efficiency
Rein Therapeutics’s return on equity (ROE) is -1.16 and return on invested capital (ROIC) is -112.59%.
Return on Equity (ROE)-1.16
Return on Assets (ROA)-1.01
Return on Invested Capital (ROIC)-112.59%
Return on Capital Employed (ROCE)-1.15
Revenue Per Employee0.00
Profits Per Employee-5.72M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio6.74
Price to Fair Value<0.01
Price to FCF-1.43
Price to Operating Cash Flow-1.42
PEG Ratio-0.04
Income Statement
In the last 12 months, Rein Therapeutics had revenue of 0.00 and earned -62.88M in profits. Earnings per share was -3.51.
Revenue0.00
Gross Profit0.00
Operating Income-65.11M
Pretax Income-64.31M
Net Income-62.88M
EBITDA-28.05M
Earnings Per Share (EPS)-3.51
Cash Flow
In the last 12 months, operating cash flow was -23.20M and capital expenditures 0.00, giving a free cash flow of -23.20M billion.
Operating Cash Flow-23.20M
Free Cash Flow-23.20M
Free Cash Flow per Share-1.01
Dividends & Yields
Rein Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.03
52-Week Price Change-50.67%
50-Day Moving Average1.63
200-Day Moving Average2.16
Relative Strength Index (RSI)31.03
Average Volume (3m)47.44K
Important Dates
Rein Therapeutics upcoming earnings date is Aug 6, 2025, TBA (Confirmed).
Last Earnings DateMay 15, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Rein Therapeutics as a current ratio of 2.38, with Debt / Equity ratio of 0.00%
Current Ratio2.38
Quick Ratio2.38
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Rein Therapeutics has paid -1.54M in taxes.
Income Tax-1.54M
Effective Tax Rate0.02
Enterprise Valuation
Rein Therapeutics EV to EBITDA ratio is 0.46, with an EV/FCF ratio of 0.58.
EV to Sales0.00
EV to EBITDA0.46
EV to Free Cash Flow0.58
EV to Operating Cash Flow0.58
Balance Sheet
Rein Therapeutics has $7.43M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$7.43M billion.
Cash & Marketable Securities$7.43M
Total Debt$0.00
Net Cash-$7.43M
Net Cash Per Share-$0.32
Tangible Book Value Per Share$326.79
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Rein Therapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside620.72% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-2.37%